ABCB1 and neoplasm: Regorafenib, a multikinase inhibitor, which targets the RAS/RAF/MEK/ERK pathway, could overcome the ABCB1‐mediated MDR and increase 3H‐PTX accumulation in ABCB1‐overexpressing tumor cells by suppressing the efflux activity of ABCB1.105